Abstract:ID 18908 Poster Board 186 Pregnane X receptor (PXR, NR1I2), a ligand-activated transcription factor, is relatively abundant in liver and intestine. Previous studies have demonstrated that PXR activation inhibits liver fibrosis, but the specific mechanisms still remain unclear. Leukocyte cell-derived chemotaxin 2 (LECT2), a downstream target of β-catenin/ T cell-specific factor 4 (TCF4) signaling, is a small-molecule protein secreted by hepatocytes. Recent study illustrated that LECT2 produced by hepatocytes participated in the progression of hepatic fibrosis by regulating angiogenesis. In the current study, we aimed to investigate whether PXR activation attenuate liver fibrosis by inhibiting LECT2 and explore its impact on β-catenin/TCF4 signaling. Additionally, we also aimed to unveil the critical role of β-catenin/TCF4-LECT2 axis in liver fibrosis and demonstrate whether PXR activation alleviates hepatic fibrosis via inhibiting β-catenin/TCF4-LECT2 axis. In the current study, carbon tetrachloride (CCl4) was used to induce liver fibrosis in C57BL/6 mice. The results showed that mouse PXR agonist pregnenolone-16α-carbonitrile (PCN) significantly attenuated hepatic fibrosis by suppressing the expression of α-smooth muscle actin (α-SMA), Collagen ? and platelet endothelial cell adhesion molecule-1 (CD31). Lymphatic vessel endothelial hyaluronan receptor 1 (LYVE1) and CD31 staining indicated that PXR activation inhibited sinusoids capillarization and central angiogenesis. Besides, immunohistochemical (IHC) staining and western blot analysis indicated that LECT2 and nuclear β-catenin were significantly downregulated after PXR activation, while total β-catenin and TCF4 didn’t alter significantly. Furthermore, reporter gene assay was performed and suggested that PXR activation inhibited the transcriptional activation of LECT2 by β-catenin/TCF4. PXR activation disrupted the interaction between β-catenin and TCF4. Co-Immunoprecipitation (Co-IP) assays further indicated that PXR potentially interacted with β-catenin and TCF4 simultaneously. Moreover, to clarify whether disrupting β-catenin/TCF4 interaction alleviated liver fibrosis, β-catenin/TCF4 inhibitor LF3 was used to evaluate its effect on liver fibrosis. The results showed the inhibition of β-catenin/TCF4 interaction decreased the expression level of LECT2 and alleviated liver fibrosis. In addition, AAV-Lect2 mice was used and we found that PXR activation failed to protect liver from fibrosis in AAV-Lect2 mice, which further confirmed that PXR attenuated hepatic fibrosis by inhibiting LECT2. Finally, we clarified that long-term treatment of PCN had no risk for carcinogenesis or promoting tumor formation induced by diethylnitrosamine (DEN), indicating the safety of long-term activation of PXR. Taken together, this study demonstrated a new mechanism that PXR attenuated liver fibrosis by disrupting β-catenin/TCF4 interaction and suppressing the expression level of LECT2. The crosstalk between PXR and β-catenin/TCF4 signaling was also clarified. These findings provide new evidence and theoretical basis for PXR as potential drug target for liver fibrosis.

PXR Activation Attenuates Liver Fibrosis by Down-Regulating LECT2 and Disrupting -Catenin/tcf4 Interaction

Pregnane X receptor activation alleviates renal fibrosis in mice via interacting with p53 and inhibiting the Wnt7a/β-catenin signaling

Activation of pregnane X receptor protects against cholestatic liver injury by inhibiting hepatocyte pyroptosis

Regulation Of Insulin Resistance And Adiponectin Signaling In Adipose Tissue By Liver X Receptor Activation Highlights A Cross-Talk With Ppar Gamma

Impaired adipose expansion caused by liver X receptor activation is associated with insulin resistance in mice fed a high-fat diet.

C1q/tumor Necrosis Factor-Related Protein-3 Acts As a Target Treating Hepatic Fibrosis

Peroxisome proliferator-activated receptor gamma inhibits hepatic fibrosis in rats.

PXR Functionally Interacts with NF-κB and AP-1 to Downregulate the Inflammation-Induced Expression of Chemokine CXCL2 in Mice

Activation of PXR Inhibits LPS-induced NF-κB Activation by Increasing IκBα Expression in HepG2 Cells

PPARβ/δ attenuates hepatic fibrosis by reducing SMAD3 phosphorylation and p300 levels via AMPK in hepatic stellate cells

Astilbin alleviates hepatic fibrosis through PXR-PINK1/Parkin pathway: A new strategy by regulating hepatic stellate cells-macrophage crosstalk

P2X7 Receptor Inhibitor Suppressed Extracellular ATP/LPS-primed Human Hepatic Stellate Cells Activation Via Downregulating NLRP3 Inflammasome

PPAR Gamma Inhibits Growth of Rat Hepatic Stellate Cells and TGF Beta-Induced Connective Tissue Growth Factor Expression

Effect of the regulation of retinoid X receptor-α gene expression on rat hepatic fibrosis.

The reversal of PXR or PPARα activation-induced hepatomegaly

PXR Mediated Protection Against Liver Inflammation by Ginkgolide A in Tetrachloromethane Treated Mice

P2X7R orchestrates the progression of murine hepatic fibrosis by making a feedback loop from macrophage to hepatic stellate cells

Total flavonoids extracted from Penthorum chinense Pursh mitigates CCl4-induced hepatic fibrosis in rats via inactivation of TLR4-MyD88-mediated NF-κB pathways and regulation of liver metabolism

Paeoniflorin promotes PPARγ expression to suppress HSCs activation by inhibiting EZH2-mediated histone H3K27 trimethylation

Peroxisome Proliferator-Activated Receptor-Γ Cross-Regulation of Signaling Events Implicated in Liver Fibrogenesis

Activation of farnesoid X receptor attenuates liver injury in MRL/lpr lupus mice